tetano
Editor, Senior Moderator
Vaccine. 2013 Jun 4. pii: S0264-410X(13)00632-4. doi: 10.1016/j.vaccine.2013.05.044. [Epub ahead of print]
Influenza vaccine: Development of a novel intranasal and subcutaneous recombinant adjuvant.
Segura-Vel?zquez R, Cervantes J, Acosta E, S?nchez-Betancourt I, Villalobos N, Rodarte LF, Restelli M, Fragoso G, Sciutto E.
Source
Instituto de Investigaciones Biom?dicas, Universidad Nacional Aut?noma de M?xico, M?xico 04510, D.F., Mexico.
Abstract
The synthetic peptide GK-1, derived from Taenia crassiceps, enhances the protection induced by human influenza vaccine in both young and aged mice. Herein, the adjuvant properties of GK-1 fused to the pVIII protein of a heat-inactivated phagemid vector (FGK1) when co-administered with the influenza vaccine were assessed, to evaluate its feasibility as a low-cost adjuvant. In mice, FGK1 significantly increased the expected IgG and IgA anti-influenza antibody levels both in sera and in bronchoalveolar fluids when intranasally or subcutaneously co-administered with influenza vaccine. Single-dose pig co-immunization with FGK1 and influenza vaccine induced serum levels of IgG anti-influenza antibodies similar to those elicited by a two-dose immunization with the influenza vaccine alone. Preclinical evaluation of FGK1 with the influenza vaccine is currently in progress, in order to recommend its use for veterinary purposes.
Copyright ? 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.
PMID:
23746458
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23746458
Influenza vaccine: Development of a novel intranasal and subcutaneous recombinant adjuvant.
Segura-Vel?zquez R, Cervantes J, Acosta E, S?nchez-Betancourt I, Villalobos N, Rodarte LF, Restelli M, Fragoso G, Sciutto E.
Source
Instituto de Investigaciones Biom?dicas, Universidad Nacional Aut?noma de M?xico, M?xico 04510, D.F., Mexico.
Abstract
The synthetic peptide GK-1, derived from Taenia crassiceps, enhances the protection induced by human influenza vaccine in both young and aged mice. Herein, the adjuvant properties of GK-1 fused to the pVIII protein of a heat-inactivated phagemid vector (FGK1) when co-administered with the influenza vaccine were assessed, to evaluate its feasibility as a low-cost adjuvant. In mice, FGK1 significantly increased the expected IgG and IgA anti-influenza antibody levels both in sera and in bronchoalveolar fluids when intranasally or subcutaneously co-administered with influenza vaccine. Single-dose pig co-immunization with FGK1 and influenza vaccine induced serum levels of IgG anti-influenza antibodies similar to those elicited by a two-dose immunization with the influenza vaccine alone. Preclinical evaluation of FGK1 with the influenza vaccine is currently in progress, in order to recommend its use for veterinary purposes.
Copyright ? 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.
PMID:
23746458
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23746458